DLG1-AS1: A Potential Drug Target and Biomarker (G100507086)

Target Name: DLG1-AS1

NCBI ID: G100507086

Other Name(s): AC092937.2 | DLG1 antisense RNA 1

DLG1-AS1: A Potential Drug Target and Biomarker

DLG1-AS1, also known as ALDH1 gene 18.2, is a gene that encodes a protein known as NAD+-dependent cytosine deaminase. This protein plays a crucial role in the detoxification of xenobiotics, such as those found in drugs, pesticides, and environmental toxins. The NAD+-dependent cytosine deaminase enzyme is a key enzyme in this detoxification process, and its function is critical for the survival of living organisms.

Recent studies have identified DLG1-AS1 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This protein has also been shown to play a key role in the development and progression of certain diseases, which makes it an attractive target for drug development.

Potential Drug Target

DLG1-AS1 has been shown to be involved in a variety of cellular processes that are important for human health, including the detoxification of xenobiotics and the regulation of cell growth and differentiation. As a result, it has been identified as a potential drug target for a variety of diseases.

One of the main potential drug targets for DLG1-AS1 is the detoxification of xenobiotics. Many drugs and environmental toxins are xenobiotics that can cause harm to the body if not properly metabolized or eliminated. The NAD+-dependent cytosine deaminase enzyme is involved in this detoxification process, and its function is critical for the survival of living organisms. Therefore, drugs that can inhibit the activity of this enzyme could be an effective treatment for a variety of xenobiotics-related diseases.

Another potential drug target for DLG1-AS1 is the regulation of cell growth and differentiation. The NAD+-dependent cytosine deaminase enzyme has been shown to play a role in the regulation of cell growth and differentiation, and its function is critical for the development and maintenance of normal tissues. Therefore, drugs that can inhibit the activity of this enzyme could be an effective treatment for a variety of diseases that involve the regulation of cell growth and differentiation, such as cancer.

Potential Biomarker

DLG1-AS1 has also been identified as a potential biomarker for a variety of diseases. The NAD+-dependent cytosine deaminase enzyme is involved in the detoxification of xenobiotics, which can be used as a biomarker for a variety of diseases. For example, the detoxification of environmental toxins, such as those found in drugs, pesticides, and other environmental hazards, can be used as a biomarker for a variety of diseases, including cancer and neurodegenerative diseases.

In addition to its role in disease detoxification, DLG1-AS1 has also been shown to play a key role in the development and progression of certain diseases. The NAD+-dependent cytosine deaminase enzyme has been shown to be involved in the development and progression of diseases such as cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, the levels of this protein can be used as a biomarker for the early detection and diagnosis of these diseases.

Conclusion

In conclusion, DLG1-AS1 is a gene that encodes a protein involved in the detoxification of xenobiotics and the regulation of cell growth and differentiation. Its function is critical for the survival of living organisms, and recent studies have identified it as a potential drug target and biomarker for a variety of diseases. Further research is needed to fully understand the role of DLG1-AS1 in human health and disease, and to develop effective treatments for a variety of diseases associated with its dysfunction.

Protein Name: DLG1 Antisense RNA 1

More Common Targets